Clarivate Is 'Cheap' for a Reason: The $4 Billion Debt Under a $1.9 Stock

The warning about Clarivate (NYSE: CLVT) starts the way most cheap stocks do: a price that looks like a gift. The shares trade near $1.91, down roughly 55% over the past year and more than 40% this year, after a slide that has carried them from a 52-week high above $4 to a low near $1.66. At that price the whole company is worth about $1.2 billion. But here is the line that reframes everything below it: Clarivate carries roughly $4 billion of net debt against that $1.2 billion stock-market value. The equity is the thin top layer of a business the creditors mostly own.

That gap is not a headline trick. It is the arithmetic the price is trying to tell you, and the thing a buyer of CLVT is actually signing up for.

The story the adjusted numbers tell

Clarivate is an information business — Web of Science, patent analytics, research intelligence — built into a public company the acquisitive way. It was carved out of Thomson Reuters in 2016 and then stacked through debt-financed deals, the biggest being the roughly $5.3 billion purchase of ProQuest in 2021. On paper it looks profitable and even high-margin. For 2025 it reported adjusted EBITDA just above $1 billion, an adjusted net income of $468 million, and recurring revenue that reached 88% of the total.

Here is the accounting that deserves a closer look. The same year, on a GAAP basis, Clarivate reported a net loss of $201 million. In 2024 the GAAP net loss was even larger, at about $637 million. An operating business does not routinely lose money on one accounting and make $468 million on another unless the difference is doing real work. The difference is a specific, recurring category of cost: amortization of the intangibles purchased in all those acquisitions — more than $350 million in the first half of 2026 alone — plus impairments and other non-cash charges.

This is the familiar shape of an acquisition-heavy income statement. Management reports "adjusted EBITDA" and "adjusted EPS" that add back the amortization of acquired intangibles every year. That makes recurring profitability look durable. But the intangibles being amortized are not an artifact — they are the price Clarivate paid, mostly with borrowed money, for the very revenue it reports. The "adjusted" profit invites you to treat the cost of the acquisitions as if it never happened, while the interest on the debt used to make those acquisitions still shows up as a cash cost every quarter.

Follow the same dollar into the cash-flow statement

Now reconcile the adjusted profit with what actually reached the shareholders, because that is where the leverage shows itself. In 2025 Clarivate generated free cash flow of $365 million. In the same year it paid $265 million in net interest. So more than two-thirds of the cash the business produced went to service the debt before a dollar was left for shareholders, buybacks, or principal. Management also spent about $225 million buying back shares in 2025 — cash going out the door to support the stock even as a company carrying more than $4 billion of debt and barely growing.

What does "barely growing" mean precisely? Organic revenue was essentially flat in 2025, down 0.1%. In the second quarter of 2026, total revenue fell 5.5% to $587 million, with organic revenue down 1.5% even as management pushed annual contract value to 1.5% organic growth thanks mostly to pricing. Full-year 2026 guidance points to organic ACV growth of just 2% to 3%. For a company trading at roughly 8 times enterprise value to EBITDA — versus 13 to 16 times for far faster-growing peers like RELX and S&P Global — the market is not paying a growth premium. It is paying a discount, and the discount starts with the balance sheet.

The empire is being unwound at a loss

The clearest evidence that the acquisition math did not work sits in the impairments. In the second quarter of 2026 Clarivate took a $221.7 million goodwill impairment and posted a $268.6 million net loss. And it is now selling its Life Sciences & Healthcare segment to the private firm Altaris for $600 million — $500 million in cash at closing, $25 million deferred, and a $75 million seller note — expecting another roughly $225 million to $250 million in goodwill impairment on the deal. Management says it will use about $500 million of the proceeds to retire notes due in 2028 and 2029.

Read that sequence as a document trail. A company built by paying up to acquire businesses is now selling one of those businesses for cash to reduce the debt it took on to acquire others, writing down goodwill as it does. This is not fraud, and nothing here requires alleging one. It is a growth-by-acquisition model reaching the point where the acquisitions are being reversed to fix the financing that paid for them. The investor response to the second-quarter report — earnings per share beat the number, revenue missed it, and the stock still fell — reflects exactly this recognition.

What the risk actually is

So the "risk of performing badly" is not a scandal waiting to be exposed. It is structural, and it has three possible paths.

The cooperative path: the Altaris sale closes near the end of 2026, the $500 million of proceeds retires notes, net debt drops toward the $3.5 billion range, and interest coverage improves. Credit agency Fitch has already revised its outlook on the debt to positive even while expecting leverage to stay above 4.0 times EBITDA for a while. Deleveraging that works is real progress — the company reduces its debt, FCF continues near $365 million to $435 million guided for 2026, and the equity stops bleeding value to interest.

The slog path: revenue keeps grinding along at zero to a few percent organic growth, adjusted EBITDA stays near $1 billion but GAAP losses and impairment charges keep recurring as old acquisitions are re-marked, and nearly all of the free cash flow keeps going to debt service. The stock can stay cheap indefinitely while the value is trapped inside the balance sheet, going to creditors rather than to the equity that last in line.

The downside path: growth disappoints or another markdown hits at a moment of thin equity. At $1.2 billion of market value on top of $4 billion of net debt, the equity is the layer that absorbs the first dollar of any adverse surprise. That is the mathematical core of why a bargain-priced share in a company with a 40%-plus adjusted margin is not automatically safe.

The shareholder invoice is simple to state. Roughly 75 cents of every dollar of free cash flow in 2025 went to interest on debt raised to buy businesses whose value has since been written down. The price already reflects much of this — the stock is down by more than half over the past year — but a beaten-down price and a cheap-sounding multiple are not cushions. They are the market's way of saying the real claim on this company's cash sits one layer above the common stock.

The next settling events are already dated. The Altaris closing is expected by the end of 2026. If it lands on time and the balance sheet deleverages on schedule, the CLVT risk case is a slow, lawful grind with real but modest equity upside. If the revenue disappointment that has become routine in this business accelerates while the debt remains, the thin equity layer is what pays for it. For a buyer, the question is not whether $1.91 is a low number. It is whether you are willing to be the last claimant on a business that is still mostly someone else's.